ARD-3150-1202: A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin in the Management of Chronic Lung Infections with Pseudomonas aeruginosa in Subjects with Non-Cystic Fibrosis Bronchiectasis, including 28 Day Open-Label Extension (ORBIT-4)
A study for subjects with non-cystic fibrosis bronchiectasis (NCFB) using study drug Pulmaquin to manage chronic lung infections
Sponsor: Aradigm Corporation
Enrolling: Male and Female Patients
IRB Number: AAAN6253
U.S. Govt. ID: NCT02104245
Contact: Kristina Rivera: 212-305-4675 /
Additional Study Information: The purpose of this study is to assess how effective the study drug Pulmaquin is in the management of chronic lung infections with Pseudomonas aeruginosa in subjects with non cystic fibrosis (nonCF) bronchiectasis by evaluating the time to first pulmonary exacerbation. A pulmonary exacerbation is defined as the new appearance or worsening in 4 or more of already present specific respiratory signs and symptoms including: cough, wheezing, chest congestion or shortness of breath, fever (38C or 98.6F), exercise tolerance and lung function tests, malaise, fatigue or lethargy, chest sounds, sputum production and x-ray findings of the lung.
This study is closed
Emily DiMango, MD
Do You Qualify?
Do you have a confirmed diagnosis of non-CF bronchiectasis? Yes No
Do you have a history of Pseudomonas aeruginosa respiratory infections? Yes No
Have you had at least two pulmonary exacerbations treated with antibiotics in the previous year? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Kristina Rivera